Methylene blue is associated with poor outcomes in vasoplegic shock

Area of Science:

• Cardiovascular Surgery
• Pharmacology
• Critical Care Medicine

Background:

• Vasoplegia is a common complication during cardiac surgery with cardiopulmonary bypass.
• Methylene blue is sometimes used to treat vasoplegia.
• The impact of methylene blue on patient outcomes requires further investigation.

Purpose of the Study:

• To investigate the association between methylene blue treatment for vasoplegia and patient morbidity and mortality.
• To evaluate the safety and efficacy of methylene blue in cardiac surgery patients.

Main Methods:

• Retrospective analysis of adult patients undergoing cardiac surgery with cardiopulmonary bypass between 2007 and 2008.
• Patients were divided into two groups: those who received methylene blue and those who did not.
• Data on preoperative, intraoperative, and outcome variables were collected and analyzed.

Main Results:

• Patients receiving methylene blue exhibited higher in-hospital mortality, increased compilation of morbidities, renal failure, and hyperbilirubinemia.
• Methylene blue use was an independent predictor of in-hospital mortality, morbidity, and hyperbilirubinemia (p<0.007).
• Propensity score matching confirmed the association with morbidity but not mortality.

Conclusions:

• Methylene blue treatment for vasoplegia is independently associated with adverse outcomes in cardiac surgery patients.
• A comprehensive risk-benefit assessment is crucial before administering methylene blue.
• Consideration should be given to using methylene blue primarily as a rescue therapy rather than first-line treatment.